A Clinical Study to Assess the Effect of Tisina Complex on Cognitive Health in Individuals With Mild Cognitive Impairment

Vedic Lifesciences

Status: Enrolling

Conditions: Cognitive Health

Treatments: Dietary Supplement: Arm 2: Placebo (Microcrystalline Cellulose); Dietary Supplement: Arm 1: TisinaTM complex

Study type: Interventional

Funder types: Industry

Identifiers

NCT06859346

BCH/240702/IP/MCI

Details and patient eligibility

About

The present study is a randomized, placebo-controlled, double-blind, parallel-group clinical study designed to assess the effects of IP in individuals with mild cognitive impairment and Tinnitus as compared to a placebo. Approximately 112 individuals aged between 30 and 75years will be screened. Considering a screen failure of 25%, approximately 84 individuals will be randomized in a ratio of 1:1 to receive either the active or placebo. The study will have at least 64 completed participants i.e. 32 participants in each study arm after accounting for adropout/withdrawal rate of 25% at the end of the study. The intervention and follow up duration for all the study participants will be 90 days.

Enrollment: 84 estimated patients

Sex: All

Ages: 30 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Males and females between 30 - 75 years old (both values included).
2. Individuals with mild cognitive impairment as indicated by Addenbrooke's Cognitive Examination (ACE) III score between 61 - 82 (both values included).
3. Individuals with subjective tinnitus with normal hearing or up to moderate sensorineural hearing loss for more than 6 months' duration.
4. Tinnitus maskable with noise of at least 5 decibels assessed by audiometry.
5. Individuals with a THI score between 18 to 56 (both values included).
6. Progressive cognitive complaints like stress, disturbed sleep etc. reported by participant or caregiver.
7. Individuals willing to provide a signed and dated informed consent and authorization to use personal health information in accordance with local and national guidance and regulations.
8. Individuals willing to comply with all procedures as outlined in the informed consent.

Exclusion criteria

1. Individuals with a medical history of heart disease, respiratory disorders, seizure disorders, metabolic syndrome or other chronic health conditions requiring medication.
2. Clinically diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD)
3. Clinically diagnosed with Alzheimer's disease.
4. Individuals with clinically significant psychiatric or neurological states, neurodegenerative disorders such as Parkinson's disease & fronto-temporal dementia, etc, that may account for cognitive impairment.
5. Individuals of objective (pulsatile) tinnitus.
6. Individuals suffering with any congenital anomalies which may lead to any otological problem.
7. Individuals suffering from any infective otological problem.
8. Individuals suffering from any otological problem other than tinnitus and sensorineural hearing.
9. Individuals whose tinnitus resulted from acute acoustic trauma, sudden deafness or traumatic head or neck injury.
10. Individuals taking any ototoxic or potentially tinnitus-inducing medication (e.g., aminoglycosides, chemotherapeutics, loop diuretics, high doses of aspirin or quinine).
11. Individuals with Meniere's disease, otosclerosis and acute or chronic otitis media.
12. Individuals with history and/or presence significant gastrointestinal disease, active malignant diseases, autoimmune diseases, haemorrhagic diathesis, cardiovascular, renal or hepatic disorders, psychiatric disorders, thyroid disease or any other acute or chronic disease.
13. Individuals who are not willing to maintain their medication, diet or physical activity habits during the study.
14. Individuals with uncontrolled Hypertension with systolic blood pressure more than or equal to 140 and/or diastolic blood pressure more than or equal to 90 mm Hg.
15. Individuals with FBG more than or equal to 126 mg/dl.
16. Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) values exceeding 2 times the upper normal limit.
17. Serum creatinine levels exceeding 1.5 times the upper normal limit.
18. Head injury immediately preceding cognitive deterioration.
19. History of uncontrolled migraine headaches, severe sleep disorders.
20. Use of psychotropic drugs or any other drug or supplement such as nootropics that may significantly affect cognitive functioning during the month prior to psychometric testing.
21. Use of any experimental medication or OTC medication or herbal treatment such as hesperidin, diosmin and other flavonoids within 1 month prior to screening.
22. Females taking any oral contraceptives.
23. Current smokers.
24. Consumption of excessive amount of caffeine i.e. ≥ 4 cups daily (> 500 mg per day).
25. History of drug, substance or alcohol addiction or abuse within the past 12 months.
26. Prior participation in a clinical study in the past 90 days before screening.
27. Females who are pregnant/planning to be pregnant or currently lactating.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

84 participants in 2 patient groups, including a placebo group

Arm 1: TisinaTM complex

Active Comparator group

Description:

Route of administration: Oral. Dose: 500 mg (2 caplets) at a single time. Regimen: Take 2 caplets, three times a day (total of 6 caplets daily) with meals.

Treatment:

Dietary Supplement: Arm 1: TisinaTM complex

Arm 2: Placebo (Microcrystalline Cellulose)

Placebo Comparator group

Description:

Route of administration: Oral. Dose: 500 mg (2 caplets) at a single time. Regimen: Take 2 caplets, three times a day (total of 6 caplets daily) with meals.

Treatment:

Dietary Supplement: Arm 2: Placebo (Microcrystalline Cellulose)